EULAR 2025: How do risk factors impact progression to Psoriatic Arthritis?

0 SAR
Checkout

Overview

Early identification of patients with PsO who are at high risk of progressing to PsA is essential. Prof. Coates emphasised that addressing modifiable risk factors, such as nail disease and skin inflammation, as well as supporting weight loss in patients with elevated BMI may help reduce the risk of PsA. Additionally, emerging evidence suggests that early biologic treatment in PsO, before joint symptoms appear, may prevent PsA progression and limit long-term joint damage

This Class for

  • Physician
  • Resident / Fellow

What I will learn?

  • Highlight the risk factors of progression to PsA and understand how early biologic treatment in PsO might prevent PsA progression

    Disclaimer

    This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
    (This information/content is intended to Health Care Providers only)

    For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com

    24 /7 mobile: +966 567 868 843, Working hours Tel: +966 11 461 7800 , Ext: 1

    For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com

    For further information, please contact:

    Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com
    Please go to PDF Material for prescribing information.

    PP-LI-SA-0128

Related Classes